Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A, Tada H, Watanabe G, Nemoto N, Nakagawa S, Ishida T, Ohuchi N. Miyashita M, et al. Among authors: nemoto n. Breast Cancer Res Treat. 2014 Dec;148(3):525-34. doi: 10.1007/s10549-014-3197-y. Epub 2014 Nov 14. Breast Cancer Res Treat. 2014. PMID: 25395319
Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
McNamara KM, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T, Nakamura Y, Suzuki T, Nemoto N, Miyashita M, Tamaki K, Ishida T, Ohuchi N, Sasano H. McNamara KM, et al. Among authors: nemoto n. Cancer Sci. 2013 May;104(5):639-46. doi: 10.1111/cas.12121. Epub 2013 Mar 15. Cancer Sci. 2013. PMID: 23373898 Free PMC article.
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.
McNamara KM, Yoda T, Nurani AM, Shibahara Y, Miki Y, Wang L, Nakamura Y, Suzuki K, Yang Y, Abe E, Hirakawa H, Suzuki T, Nemoto N, Miyashita M, Tamaki K, Ishida T, Brown KA, Ohuchi N, Sasano H. McNamara KM, et al. Among authors: nemoto n. Breast Cancer Res Treat. 2014 Jun;145(2):281-93. doi: 10.1007/s10549-014-2942-6. Epub 2014 Apr 9. Breast Cancer Res Treat. 2014. PMID: 24715382
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M, Morizane C, Furukawa M, Sakai D, Komatsu Y, Nakai Y, Tsuda M, Ozaka M, Mizuno N, Muto M, Fukutomi A, Ikeda M, Tsuji A, Katanuma A, Moriwaki T, Kajiwara T, Ishii H, Negoro Y, Shimizu S, Nemoto N, Kobayashi S, Makino K, Furuse J. Ueno M, et al. Among authors: nemoto n. Cancer Med. 2021 Mar;10(6):2088-2099. doi: 10.1002/cam4.3813. Epub 2021 Feb 26. Cancer Med. 2021. PMID: 33635605 Free PMC article. Clinical Trial.
456 results